Nebojša Skrepnik

1.4k total citations
35 papers, 1.1k citations indexed

About

Nebojša Skrepnik is a scholar working on Rheumatology, Surgery and Molecular Biology. According to data from OpenAlex, Nebojša Skrepnik has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Rheumatology, 9 papers in Surgery and 6 papers in Molecular Biology. Recurrent topics in Nebojša Skrepnik's work include Osteoarthritis Treatment and Mechanisms (12 papers), Knee injuries and reconstruction techniques (5 papers) and Tendon Structure and Treatment (3 papers). Nebojša Skrepnik is often cited by papers focused on Osteoarthritis Treatment and Mechanisms (12 papers), Knee injuries and reconstruction techniques (5 papers) and Tendon Structure and Treatment (3 papers). Nebojša Skrepnik collaborates with scholars based in United States, France and Canada. Nebojša Skrepnik's co-authors include John J. Spitzer, Scott G. Edwards, Matthew L. Ramsey, David C. Karli, Grant L. Jones, Allan Mishra, Steven Sampson, Arthur C. Rettig, Gregory J. Bagby and Ion V. Deaciuc and has published in prestigious journals such as Hepatology, Cancer and The American Journal of Sports Medicine.

In The Last Decade

Nebojša Skrepnik

35 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nebojša Skrepnik United States 15 503 372 255 154 130 35 1.1k
Pongsak Yuktanandana Thailand 21 258 0.5× 535 1.4× 172 0.7× 235 1.5× 176 1.4× 42 969
Florent Eymard France 16 403 0.8× 890 2.4× 175 0.7× 157 1.0× 253 1.9× 50 1.2k
Win Min Oo Australia 19 522 1.0× 946 2.5× 275 1.1× 162 1.1× 282 2.2× 52 1.4k
M. Uchida Japan 12 272 0.5× 450 1.2× 85 0.3× 302 2.0× 109 0.8× 23 1.1k
J.-P. Pelletier Canada 18 526 1.0× 919 2.5× 255 1.0× 154 1.0× 291 2.2× 42 1.3k
Chang‐Hsun Hsieh Taiwan 20 271 0.5× 179 0.5× 77 0.3× 214 1.4× 31 0.2× 69 1.2k
V. Stojanovic‐Susulic Netherlands 19 434 0.9× 1.1k 3.0× 154 0.6× 295 1.9× 325 2.5× 28 1.6k
M Pattrick United Kingdom 18 447 0.9× 672 1.8× 205 0.8× 79 0.5× 239 1.8× 28 1.3k
R. W. Moskowitz United States 14 349 0.7× 720 1.9× 108 0.4× 115 0.7× 416 3.2× 28 1.2k
Duarte Costa Pereira Portugal 8 361 0.7× 629 1.7× 101 0.4× 129 0.8× 249 1.9× 12 1.1k

Countries citing papers authored by Nebojša Skrepnik

Since Specialization
Citations

This map shows the geographic impact of Nebojša Skrepnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nebojša Skrepnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nebojša Skrepnik more than expected).

Fields of papers citing papers by Nebojša Skrepnik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nebojša Skrepnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nebojša Skrepnik. The network helps show where Nebojša Skrepnik may publish in the future.

Co-authorship network of co-authors of Nebojša Skrepnik

This figure shows the co-authorship network connecting the top 25 collaborators of Nebojša Skrepnik. A scholar is included among the top collaborators of Nebojša Skrepnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nebojša Skrepnik. Nebojša Skrepnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sax, Oliver C., Martin G. Gesheff, Dilawar Ajani, et al.. (2022). A Novel Mobile App-Based Neuromuscular Electrical Stimulation Therapy for Improvement of Knee Pain, Stiffness, and Function in Knee Osteoarthritis: A Randomized Trial. Arthroplasty Today. 15. 125–131. 11 indexed citations
3.
Yazıcı, Yusuf, T.E. McAlindon, Allan Gibofsky, et al.. (2021). A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthritis and Cartilage. 29(5). 654–666. 73 indexed citations
4.
Dakin, Paula, Alan Kivitz, Joseph Gimbel, et al.. (2020). Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial. Annals of the Rheumatic Diseases. 80(4). 509–517. 26 indexed citations
5.
Yazıcı, Yusuf, Timothy E. McAlindon, Allan Gibofsky, et al.. (2019). Efficacy and safety from a phase 2B trial of SM04690, a novel, intra-articular, WNT pathway inhibitor for the treatment of osteoarthritis of the knee. Osteoarthritis and Cartilage. 27. S503–S503. 9 indexed citations
6.
7.
8.
Yazıcı, Yusuf, Timothy E. McAlindon, Roy Fleischmann, et al.. (2017). A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis and Cartilage. 25(10). 1598–1606. 108 indexed citations
9.
10.
Jones, Graeme, et al.. (2012). Efficacy and Safety of Collagenase Clostridium Histolyticum Injection for Dupuytren Contracture: Short-Term Results From 2 Open-Label Studies. The Journal Of Hand Surgery. 38(1). 2–11. 90 indexed citations
11.
Garrett, William E., Christopher C. Kaeding, Neal S. ElAttrache, et al.. (2011). Novel Drug OMS103HP Reduces Pain and Improves Joint Motion and Function for 90 Days After Arthroscopic Meniscectomy. Arthroscopy The Journal of Arthroscopic and Related Surgery. 27(8). 1060–1070. 7 indexed citations
12.
Skrepnik, Nebojša, et al.. (2009). The Relationship Between Skeletal Muscle Serum Markers and Primary THA: A Pilot Study. Clinical Orthopaedics and Related Research. 467(7). 1747–1752. 28 indexed citations
13.
Skrepnik, Nebojša, et al.. (1999). RECOMBINANT ONCOTOXIN AR209 (ANTI-P185 erbB-2 ) DIMINISHES HUMAN PROSTATE CARCINOMA XENOGRAFTS. The Journal of Urology. 161(3). 984–989. 11 indexed citations
14.
Skrepnik, Nebojša, et al.. (1998). Aggressive administration of recombinant oncotoxin AR209 (anti-ErbB-2) in athymic nude mice implanted with orthotopic human non-small cell lung tumours. European Journal of Cancer. 34(10). 1628–1633. 3 indexed citations
15.
Qian, Zhong, et al.. (1997). Percutaneous implantation of non-small-cell lung carcinoma: Technique and observations. Academic Radiology. 4(9). 629–633. 10 indexed citations
16.
Skrepnik, Nebojša, et al.. (1996). Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice.. PubMed. 2(11). 1851–7. 11 indexed citations
17.
Chamulitrat, Waleé, Nebojša Skrepnik, & John J. Spitzer. (1996). ENDOTOXIN-INDUCED OXIDATIVE STRESS IN THE RAT SMALL INTESTINE. Shock. 5(3). 217–222. 36 indexed citations
18.
Chamulitrat, Waleé, Nebojša Skrepnik, & John J. Spitzer. (1996). NITROSYL COMPLEX FORMATION DURING ENDOTOXIN-INDUCED INJURY IN THE RAT SMALL INTESTINE. Shock. 5(1). 59–65. 10 indexed citations
19.
Bagby, G. J., Charles H. Lang, Nebojša Skrepnik, & J. J. Spitzer. (1992). Attenuation of glucose metabolic changes resulting from TNF-alpha administration by adrenergic blockade. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 262(4). R628–R635. 12 indexed citations
20.
Hargrove, Diane M., Nebojša Skrepnik, Charles H. Lang, Gregory J. Bagby, & John J. Spitzer. (1990). Role of insulin in the blunted glucose metabolic response of septic rats to epinephrine. Metabolism. 39(11). 1180–1185. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pongsak Yuktanandana Breakdown of academic impact, for papers by Florent Eymard Breakdown of academic impact, for papers by Win Min Oo Breakdown of academic impact, for papers by M. Uchida Breakdown of academic impact, for papers by J.-P. Pelletier Breakdown of academic impact, for papers by Chang‐Hsun Hsieh Breakdown of academic impact, for papers by V. Stojanovic‐Susulic Breakdown of academic impact, for papers by M Pattrick Breakdown of academic impact, for papers by R. W. Moskowitz Breakdown of academic impact, for papers by Duarte Costa Pereira
Rankless by CCL
2026